Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
Breast Cancer: Targets and Therapy · 2021-09 · Volume 13 · 539-557
DOI: 10.2147/bctt.s288344 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Breast Cancer: Targets and Therapy, 2021-09. Verfasst von Mohamad Adham Salkeni und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
- Department of Internal Medicine, West Virginia University, Morgantown, WV, USA.
- Department of Business, Lamar University, Houston, TX, USA.
- Departments of Clinical Pharmacy and Medicine, West Virginia University, Morgantown, WV, USA.
ORCID-Profile: Wajeeha Rizvi, Gerald M Higa
Zitieren
APA
Salkeni, M. A., Rizvi, W., Hein, K., & Higa, G. M. (2021). Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer. Breast Cancer: Targets and Therapy, Volume 13, 539-557. https://doi.org/10.2147/bctt.s288344
Vancouver
Salkeni MA, Rizvi W, Hein K, Higa GM. Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer. Breast Cancer: Targets and Therapy. 2021;Volume 13:539-557. doi:10.2147/bctt.s288344
BibTeX
@article{Salkeni2021,
author = {Salkeni, Mohamad Adham and Rizvi, Wajeeha and Hein, Kyaw and Higa, Gerald M},
title = {Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer},
journal = {Breast Cancer: Targets and Therapy},
year = {2021},
volume = {Volume 13},
pages = {539--557},
doi = {10.2147/bctt.s288344}
}
EUVIMED